No products in the cart.

Mouse Procollagen Type Ⅰ N Terminal Propeptide ELISA kit

SKU Product Brand Unit Availability Price Quantity  
EK-07-0779
Mouse Procollagen Type Ⅰ N Terminal Propeptide ELISA kit
Erpan Tech In stock

Specifications        

Product Cat#: EK-07-0779
Product name: Mouse Procollagen Type Ⅰ N Terminal Propeptide ELISA kit
Target Name: PⅠNP
Species Reactivity: Mouse
Product Size: 48/96 Tests
Sensitivity: 12.4 pg/ml
Assay range: 100-2500 pg/ml
Assay Time: 90 minutes
Platform: Colorimetric Microplate Reader
Conjugate: HRP
ELISA Type: Competitive ELISA
Detection Method: Colorimetric
Storage temperature: Store at 2-8°C
Stability: Stable within the expiration date under suggested storage conditions
Shipping condition: Wet ice
Kit Contents: Microtiter plate (1x), Enzyme conjugate (1 vial), Standard samples (6 vials),
Substrates (A & B, 2 vials), Stop solution (1 vial), Wash Solution (100x, 1 vial),
Balance solution (1 vial), Instruction (1 copy)
Other Names of Target: P1NP; N-Propeptide Of Type I Procollagen; Procollagen I Amino Terminal Propeptide
Show More

Target information

Procollagen type I propeptides are derived from collagen type I, which is the most common collagen type found in mineralized bone. In bone, collagen is synthesized by osteoblasts in the form of procollagen. This precursor contains a short signal sequence and terminal extension peptides: amino-terminal propeptide (PINP) and carboxy-terminal propeptide. These propeptide extensions are removed by specific proteinases before the collagen molecules form. Both propeptides can be found in the circulation and their concentration reflects the synthesis rate of collagen type I. Although collagen type I propeptides may also arise from other tissues (such as the skin, vessels, fibrocartilage, and tendons), most nonskeletal tissues exhibit a slower turnover than bone, and contribute very little to the circulating pool of PINP. PINP is considered the most sensitive marker of bone formation and it is particularly useful for monitoring bone formation therapies and antiresorptive therapies; it is recommended that the test be performed at baseline before starting osteoporosis therapy and again 3 to 6 months later. PINP could be detected in the circulation as the “intact” or trimeric molecule and the monomer. In osteoporosis subjects with normal renal function, the predominant form of PINP detected in circulation is the trimeric form. However, monomeric PINP fragments may accumulate in patients with renal failure or metastatic bone disease.

Provider

Erpantech Laboratory

download

MSDS-EK-07-0779.pdf (166 downloads )